-
Patent Agency Ranking
公开(公告)号：US20210386793A1
公开(公告)日：2021-12-16
申请号：US17282439
申请日：2019-10-04
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： Elisabeth LINDNER , Bastian DEHMEL , Maria ÅKERMAN
Abstract: The present invention relates to the treatment or prevention of oxalate-related disorders, more particularly to the use of a pharmaceutical composition comprising Oxalobacter formigenes in the treatment or prevention of systemic oxalosis with cardiac involvement.
-
公开(公告)号：US20210052670A1
公开(公告)日：2021-02-25
申请号：US17010570
申请日：2020-09-02
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： Elisabeth LINDNER , Maria ÅKERMAN , Anna SJÖGREN , Orla MCCALLION
Abstract: The present disclosure is related to pharmaceutical compositions and methods for treating and/or preventing oxalate-related disorders. More particularly, the present disclosure pertains to compositions comprising an oxalate-degrading bacteria Oxalobacter formigenes particularly suitable for the treatment and/or prevention of late stage hyperoxaluria characterized by high plasma-oxalate levels and a progressing decrease in kidney function.
-
公开(公告)号：US20160137701A1
公开(公告)日：2016-05-19
申请号：US14902484
申请日：2014-07-03
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： Elisabeth LINDNER , Helena COWLEY , Aaron COWLEY
CPC classification number: C07K14/195 , A61K35/74 , A61K38/00 , A61K38/164 , C12N9/0006 , C12N9/0016 , C12N9/0051 , C12N9/1014 , C12N9/1085 , C12N9/14 , C12N9/88 , C12Y101/0106 , C12Y104/01016 , C12Y108/01 , C12Y201/02001 , C12Y205/01006 , C12Y205/01009 , C12Y205/01047 , C12Y303/01001 , C12Y402/01003
Abstract: The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.
Abstract translation: 本发明涉及一种衍生自草酸降解细菌的促分泌素化合物，用于治疗受试者中草酸盐相关疾病和/或草酸盐相关不平衡，其中所述促分泌素的施用导致尿草酸盐和/或 受试者血浆草酸盐。 本发明还涉及包含这种促分泌素化合物的药物组合物，用于治疗患有草酸盐相关疾病的受试者的方法和用于制备促分泌素的方法。
-
公开(公告)号：US20220098247A1
公开(公告)日：2022-03-31
申请号：US17240542
申请日：2021-04-26
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： Elisabeth LINDNER , Helena COWLEY , Aaron COWLEY , Maria ÅKERMAN
Abstract: The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.
-
公开(公告)号：US20190125807A1
公开(公告)日：2019-05-02
申请号：US16308439
申请日：2017-06-13
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： Elisabeth LINDNER , Maria ÅKERMAN , Anna SJÖGREN , Orla MCCALLION
CPC classification number: A61K35/74 , A61K9/4866 , A61K9/4891 , A61P1/00
Abstract: The present disclosure is related to pharmaceutical compositions and methods for treating and/or preventing oxalate-related disorders. More particularly, the present disclosure pertains to compositions comprising an oxalate-degrading bacteria Oxalobacter formigenes particularly suitable for the treatment and/or prevention of late stage hyperoxaluria characterized by high plasma-oxalate levels and a progressing decrease in kidney function.
-
-
-
-
Search Results
5
records
(took 0.026 seconds)
